JPMorgan analyst Jessica Fye reiterated an Overweight rating and $10.00 price target on BioCryst Pharma (NASDAQ: BCRX)The analyst comments "We ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments

Piper Sandler Reiterates Overweight Rating on BioCryst Pharma (BCRX)February 24, 2025 1:18 PM BioCryst Pharma (BCRX) Misses Q4 EPS by 6c; offers outlookFebruary 24, 2025 7:29 AM Form 8-K BIOCRYST PHARMACEUTICALS For: Feb 24February 24, 2025 7:06 AM BioCryst Reports Fourth Quarter and Full Year 2024 Financial Results and Upcoming Key MilestonesFebruary 24, 2025 7:00 AM BioCryst Announces Positive Results from APeX-P Trial for ORLADEYO® (berotralstat) in Pediatric Patients with Hereditary Angioedema Aged 2 to <12 YearsFebruary 24, 2025 6:00 AM